DelveInsight’s, “Papillary Thyroid Cancer Pipeline Insight 2023” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Papillary Thyroid Cancer pipeline landscape. It covers the Papillary Thyroid Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Papillary Thyroid Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Papillary Thyroid Cancer Pipeline Report
- DelveInsight’s Papillary Thyroid Cancer pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Papillary Thyroid Cancer treatment.
- The leading companies working in the Papillary Thyroid Cancer Market include Hoffmann-La Roche, Bristol-Myers Squibb, Purple Biotech, Helsinn Healthcare SA, and others.
- Promising Papillary Thyroid Cancer Pipeline Therapies in the various stages of development GSK2118436, Vemurafenib, SU011248, Rosiglitazone, XL184, LOXO-292, and others.
- November 2023: TYK Medicines Inc. announced a study of Phase 1 & 2 clinical trials for TY-1091. This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of TY-1091 administered orally in participants with medullary thyroid cancer (MTC), RET-altered NSCLC and other RET-altered solid tumors.
- November 2023: Famewave Ltd. announced a study of Phase 1 & 2 clinical trials for CM-24 and Nivolumab. This is an open-label, multicenter, multi-dose escalation and dose expansion study in subjects with selected advanced solid tumors (Part A) and advanced metastatic pancreatic cancer (Parts C & D) to evaluate the safety and tolerability of CM-24 in combination with nivolumab. In Part C of the study gemcitabine/nab-paclitaxel or Nal-IRI/5-FU/LV will be administered subsequent to CM24 and nivolumab. CM24, nivolumab and gemcitabine/nab-paclitaxel or Nal-IRI/5-FU/LV are administered intravenously.
- November 2023: Hoffmann- La Roche announced a study of Phase 1 & 2 clinical trials for Pralsetinib (BLU-667). This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in participants with medullary thyroid cancer (MTC), RET-altered NSCLC and other RET-altered solid tumors.
- November 2023: M.D. Anderson Cancer Center announced a study of Phase 2 clinical trials for Vemurafenib. The goal of this clinical research study is to learn about how vemurafenib may affect certain biomarkers in patients with PTC. Biomarkers are in the blood/tissue and may be related to your reaction to the study drug. The safety of this drug will also be studied. Vemurafenib is designed to block the BRAF gene mutation. This mutation causes cancer and cancer growth. By blocking this mutation, the drug may kill the cancer cells with the mutation and/or stop the tumor from growing.
Request a sample and discover the recent advances in Papillary Thyroid Cancer Treatment Drugs @ Papillary Thyroid Cancer Pipeline Report
In the Papillary Thyroid Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Papillary Thyroid Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Papillary Thyroid Cancer Overview
Papillary thyroid carcinoma (PTC) is an epithelial malignancy showing evidence of follicular cell differentiation and a set of distinctive nuclear features. It is the most frequent thyroid neoplasm and carries the best overall prognosis. The tumor usually appears as an irregular solid mass but in rare cases, it may have cystic features. One key feature of PTC is its ability to invade adjacent structures like lymphatics.
Find out more about Papillary Thyroid Cancer Therapeutics Assessment @ Papillary Thyroid Cancer Preclinical and Discovery Stage Products
Papillary Thyroid Cancer Emerging Drugs Profile
- CM-24 : Purple Biotech
- Vemurafenib: Roche
Papillary Thyroid Cancer Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the therapies for Papillary Thyroid Cancer. The Papillary Thyroid Cancer companies which have their Papillary Thyroid Cancer drug candidates in the most advanced stage, i.e. phase II include, Roche.
DelveInsight’s Papillary Thyroid Cancer pipeline report covers around 5+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Papillary Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
Papillary Thyroid Cancer Pipeline Products have been categorized under various Molecule types such as
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
Learn more about the emerging Papillary Thyroid Cancer Pipeline Therapies @ Papillary Thyroid Cancer Clinical Trials Assessment
Scope of the Papillary Thyroid Cancer Pipeline Report
- Coverage- Global
- Papillary Thyroid Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Papillary Thyroid Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Papillary Thyroid Cancer Companies- Hoffmann-La Roche, Bristol-Myers Squibb, Purple Biotech, Helsinn Healthcare SA, and others.
- Papillary Thyroid Cancer Pipeline Therapies- GSK2118436, Vemurafenib, SU011248, Rosiglitazone, XL184, LOXO-292, and others.
Dive deep into rich insights for new drugs for Papillary Thyroid Cancer Treatment, Visit @ Papillary Thyroid Cancer Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Papillary Thyroid Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Papillary Thyroid Cancer – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Vemurafenib: Roche
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- CM-24 : Purple Biotech
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Papillary Thyroid Cancer Key Companies
- Papillary Thyroid Cancer Key Products
- Papillary Thyroid Cancer- Unmet Needs
- Papillary Thyroid Cancer- Market Drivers and Barriers
- Papillary Thyroid Cancer- Future Perspectives and Conclusion
- Papillary Thyroid Cancer Analyst Views
- Papillary Thyroid Cancer Key Companies
- Appendix
For further information on the Papillary Thyroid Cancer Pipeline therapeutics, reach out to Papillary Thyroid Cancer Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
